Prescription Drugs Used in Insomnia.
Study Goal
The researchers aimed to review the effects of melatonin and its receptor agonists on sleep in adults with chronic insomnia, alongside other prescription drugs.
Results Summary
The abstract indicates that melatonin and its receptor agonists were discussed in terms of their clinical effects on sleep duration, continuity, and architecture, but specific findings are not detailed.
Population
Adults with chronic insomnia.
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
benzodiazepines and its receptor agonists | neutral | sleep duration, continuity, and architecture | adults with chronic insomnia | - | clinical effects are described | #1 |
the dual orexin receptor antagonist suvorexant | neutral | sleep duration, continuity, and architecture | adults with chronic insomnia | - | clinical effects are described | #2 |
melatonin and its receptor agonists | neutral | sleep duration, continuity, and architecture | adults with chronic insomnia | - | clinical effects are described | #3 |
sedating antidepressants | neutral | sleep duration, continuity, and architecture | adults with chronic insomnia | - | clinical effects are described | #4 |
antipsychotics | neutral | sleep duration, continuity, and architecture | adults with chronic insomnia | - | clinical effects are described | #5 |
The scope of this article is to review the effects on sleep of prescription drugs that are commonly prescribed for chronic insomnia in adults. The following groups are discussed: benzodiazepines and its receptor agonists, the dual orexin receptor antagonist suvorexant, melatonin and its receptor agonists, sedating antidepressants, and antipsychotics. Together with the neurobiologic and pharmacologic properties of these drugs, clinical effects are described, including subjective and objective effects on sleep duration, continuity, and architecture. Medical prescription information is given when available. Recently published American and European guidelines for the treatment of insomnia serve as reference frame.